Try our mobile app

Switch to company model in classical logic    *

General information

Country: IRELAND

Sector: Diagnostics and Research

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and distributes products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. The company sells its products through its direct sales force; and a network of independent distributors and strategic partners...
Website: trinitybiotech.com



Growth: Bad revenue growth rate -26.9%, there is slowdown compared to average historical growth rates 1.5%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -2.3%. On average the margin is decreasing steadily. Gross margin is normal, +38.7%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 17% of quarters (showing a gain of -$0.17 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -20.0% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 387.4% higher than minimum and 50.5% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 0.9x by EV / Sales multiple , the company can be 45.4% overvalued

Key Financials (Download financials)

Ticker: TRIB
Share price, USD:  (0.0%)1.83
year average price 0.9295  


year start price 1.0464 2023-04-27

min close price 0.3755 2023-11-27

max close price 2.4000 2024-02-23

current price 1.8300 2024-04-25
Common stocks: 38 327 571

Dividend Yield:  0.0%
Last revenue growth (y/y):  -26.9%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  1.5%
Historical growth of EBITDA:  ---
EV / Sales: 1.6x
Margin (EBITDA LTM / Revenue): -2.3%
Fundamental value created in LTM:
Market Cap ($m): 70
Net Debt ($m): 66
EV (Enterprise Value): 136
Price to Book: -2.9x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-04Seeking Alpha

Trinity Biotech plc (TRIB) Q4 2023 Earnings Call Transcript

2024-03-28GlobeNewsWire

Trinity Biotech plc to Announce Q4 and Fiscal Year 2023 Financial Results

2024-02-02Zacks Investment Research

Trinity Biotech (TRIB) to Grow in Wearable Biosensor With Buyout

2024-01-31Seeking Alpha

Trinity Biotech plc (TRIB) Acquisition of the CGM Assets of Waveform Technologies and Q3 2023 Earnings Call (Transcript)

2023-09-27GlobeNewsWire

Trinity Biotech plc to Announce Second Quarter Fiscal Year 2023 Financial Results

2023-07-03GlobeNewsWire

Trinity Biotech plc to Announce First Quarter Fiscal Year 2023 Financial Results
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol TRIB TRIB TRIB TRIB TRIB TRIB TRIB
reportedCurrency USD USD USD USD USD USD USD
cik 888 721 888 721 888 721 888 721 888 721 888 721 888 721
fillingDate 2024-02-01 2023-10-06 2023-07-10 2023-03-27 2022-12-16 2022-09-12 2022-06-30
acceptedDate 2024-02-01 11:37:17 2023-10-06 16:05:13 2023-07-10 06:02:26 2023-03-27 06:01:04 2022-12-16 10:59:21 2022-09-12 12:22:17 2022-06-30
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3 Q2
revenue 13M 15M 14M 15M 18M 20M 18M
costOfRevenue 9M 10M 9M 9M 12M 17M 12M
grossProfit 4M 4M 5M 6M 6M 2M 7M
grossProfitRatio 0.306 0.292 0.362 0.376 0.346 0.103 0.353
researchAndDevelopmentExpenses 1M 1M 1M 860 000 1M 1M 984 000
generalAndAdministrativeExpenses 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 6M 8M 8M 9M 10M 6M 7M
otherExpenses 0 0 0 0 -341 000 -1000.000 1000.000
operatingExpenses 8M 9M 9M 9M 11M 7M 8M
costAndExpenses 17M 19M 18M 19M 23M 24M 20M
interestIncome 611 000 389 000 62 000 154 000 112 000 329 000 0
interestExpense 2M 2M 4M 3M 2M 2M 18M
depreciationAndAmortization 462 000 229 000 484 000 756 000 780 000 1M 261 000
ebitda -3M -4M -3M -3M -4M -4M 9M
ebitdaratio -0.225 -0.264 -0.251 -0.213 -0.222 -0.191 0.465
operatingIncome -3M -5M -15M -4M -5M -5M -2M
operatingIncomeRatio -0.260 -0.307 -1.069 -0.264 -0.265 -0.246 -0.110
totalOtherIncomeExpensesNet -2M -2M -11M -2M -5M -4M -18M
incomeBeforeTax -6M -6M -19M -6M -10M -9M -20M
incomeBeforeTaxRatio -0.410 -0.443 -1.339 -0.426 -0.560 -0.458 -1.088
incomeTaxExpense -3000.000 222 000 -267 000 -11 000 -16 000 3000.000 -30 000
netIncome -6M -7M -6M -6M -10M -9M -10M
netIncomeRatio -0.410 -0.458 -0.431 -0.425 -0.559 -0.459 -0.526
eps -3.590 -0.880 -0.780 -0.170 -0.260 -0.230 -0.395
epsdiluted -3.590 -0.880 -0.780 -0.170 -0.260 -0.230 -0.395
weightedAverageShsOut 2M 8M 8M 38M 38M 38M 25M
weightedAverageShsOutDil 2M 8M 8M 38M 38M 38M 25M
link Link Link Link Link Link
finalLink Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-12 2022-06-30
symbol TRIB TRIB TRIB TRIB TRIB TRIB TRIB
reportedCurrency USD USD USD USD USD USD USD
cik 888 721 888 721 888 721 888 721 888 721 888 721 888 721
fillingDate 2024-02-01 2023-10-06 2023-07-10 2023-03-27 2022-12-16 2022-09-12 2022-06-30
acceptedDate 2024-02-01 11:37:17 2023-10-06 16:05:13 2023-07-10 06:02:26 2023-03-27 06:01:04 2022-12-16 10:59:21 2022-09-12 12:22:17 2022-06-30
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3 Q2
cashAndCashEquivalents 4M -13M -13M -14M 7M 0 10M
shortTermInvestments 0 19M 27M 17M 0 0 0
cashAndShortTermInvestments 4M 6M 14M 4M 7M 7M 10M
netReceivables 15M 17M 16M 15M 18M 19M 18M
inventory 20M 21M 23M 22M 23M 24M 29M
otherCurrentAssets 0 0 2M 18M 0 0 0
totalCurrentAssets 39M 44M 53M 58M 47M 50M 57M
propertyPlantEquipmentNet 2M 2M 2M 5M 6M 6M 6M
goodwill 0 0 0 0 13M 0 0
intangibleAssets 0 0 16M 0 23M 0 0
goodwillAndIntangibleAssets 16M 16M 16M 21M 35M 37M 39M
longTermInvestments 178 000 196 000 214 000 2M 0 0 0
taxAssets 2M 2M 1M 4M 4M 5M 5M
otherNonCurrentAssets 78 999 98 000 108 000 272 000 267 000 302 000 347 000
totalNonCurrentAssets 20M 20M 19M 33M 45M 48M 50M
otherAssets 0 0 0 0 0 0 0
totalAssets 59M 64M 72M 91M 92M 98M 107M
accountPayables 14M 11M 13M 13M 17M 14M 12M
shortTermDebt 210 000 2M 2M 2M 210 000 210 000 2M
taxPayables 279 000 252 000 287 000 33 000 28 000 21 000 21 000
deferredRevenue 279 001 0 0 83 000 114 000 0 0
otherCurrentLiabilities 49 999 302 000 337 000 1M -36 000 71 000 50 000
totalCurrentLiabilities 15M 13M 15M 16M 17M 15M 14M
longTermDebt 55M 65M 65M 75M 58M 58M 57M
deferredRevenueNonCurrent 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 2M 2M 2M 5M 5M 5M 5M
otherNonCurrentLiabilities 11M 1M 2M 2M 14M 62M 15M
totalNonCurrentLiabilities 68M 68M 69M 82M 77M 77M 77M
otherLiabilities 0 0 0 0 0 0 0
capitalLeaseObligations 0 13M 13M 14M 14M 0 2M
totalLiabilities 83M 81M 83M 98M 94M 91M 91M
preferredStock 0 0 0 0 0 0 0
commonStock 2M 2M 2M 2M 2M 2M 2M
retainedEarnings -49M -42M -36M -31M -27M -18M -9M
accumulatedOtherComprehensiveIncomeLoss 1M -6M -6M -6M -6M -6M -5M
othertotalStockholdersEquity 22M 28M 28M 28M 28M 28M 28M
totalStockholdersEquity -24M -17M -11M -7M -2M 7M 16M
totalEquity -24M -17M -11M -7M -2M 7M 16M
totalLiabilitiesAndStockholdersEquity 59M 64M 72M 91M 92M 98M 107M
minorityInterest 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 59M 64M 72M 91M 92M 98M 107M
totalInvestments 178 000 19M 28M 2M 0 0 0
totalDebt 55M 67M 67M 77M 58M 58M 59M
netDebt 51M 80M 81M 91M 52M 58M 49M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol TRIB TRIB TRIB TRIB TRIB TRIB TRIB
reportedCurrency USD USD USD USD USD USD USD
cik 888 721 888 721 888 721 888 721 888 721 888 721 888 721
fillingDate 2024-02-01 2023-10-06 2023-07-10 2023-03-27 2022-12-16 2022-09-12 2022-06-30
acceptedDate 2024-02-01 11:37:17 2023-10-06 16:05:13 2023-07-10 06:02:26 2023-03-27 06:01:04 2022-12-16 10:59:21 2022-09-12 12:22:17 2022-06-30
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3 Q2
netIncome -6M -7M -6M -6M -10M -9M -22M
depreciationAndAmortization 462 000 229 000 484 000 602 000 668 000 744 000 261 000
deferredIncomeTax 0 222 000 -267 000 -11 000 -16 000 3000.000 -29 000
stockBasedCompensation 0 738 000 975 000 1M 1M 119 000 122 000
changeInWorkingCapital 2M -2M -1M -1M 2M 153 000 -2M
accountsReceivables 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0
accountsPayables 0 0 0 0 0 0 0
otherWorkingCapital 0 0 0 0 0 0 0
otherNonCashItems 2M 3M 2M 3M 8M 9M 25M
netCashProvidedByOperatingActivities -966 000 -5M -4M -3M 2M 676 000 956 000
investmentsInPropertyPlantAndEquipment -891 000 -620 000 -564 000 -629 000 -1M -1M 383 000
acquisitionsNet 0 -266 000 28M 0 0 0 0
purchasesOfInvestments 0 0 0 -700 000 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0
otherInvestingActivites 1.000 0 0 0 0 0 -1M
netCashUsedForInvestingActivites -890 999 -886 000 28M -1M -1M -1M -1M
debtRepayment 0 -571 000 -11M -599 000 -600 000 -684 000 -36M
commonStockIssued 0 0 0 0 317 000 0 25M
commonStockRepurchased 0 0 0 0 -130 000 0 0
dividendsPaid 0 0 0 0 0 0 0
otherFinancingActivites 0 -2M -3M 2M -1M -2M 11M
netCashUsedProvidedByFinancingActivities -555 000 -2M -13M 2M -2M -2M 484 000
effectOfForexChangesOnCash -158 001 14 000 85 000 14 000 32 000 -179 000 -153 000
netChangeInCash -3M -8M 10M -2M -676 000 -3M 441 000
cashAtEndOfPeriod 4M 6M 14M 4M 7M 7M 10M
cashAtBeginningOfPeriod 6M 14M 4M 7M 7M 10M 10M
operatingCashFlow -966 000 -5M -4M -3M 2M 676 000 956 000
capitalExpenditure -891 000 -620 000 -564 000 -629 000 -1M -1M -1M
freeCashFlow -2M -5M -5M -3M 1M -648 000 -77 000
link Link Link Link Link Link
finalLink Link Link Link Link Link

Earning call transcript

2024 q1
2024-04-04 ET (fiscal 2023 q4)
2023 q3
2023-10-03 ET (fiscal 2023 q2)
2022 q4
2023-03-23 ET (fiscal 2022 q4)
2022 q3
2022-12-15 ET (fiscal 2022 q3)
2022 q2
2022-06-30 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-03-08 15:03 ET
Trinity Biotech Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
2024-02-15 17:34 ET
Trinity Biotech Plc Finalizes Effective Date of ADS Ratio Change
2024-02-13 14:00 ET
Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change
2024-02-08 13:30 ET
Trinity Biotech to Present at Emerging Growth Conference
2024-02-07 13:30 ET
Trinity Biotech Announces Application for Early Sjogrens Syndrome Test Panel PLA Code
2024-01-31 12:05 ET
Trinity Biotech Announces Q3 2023 Financial Results & Business Update
2024-01-31 12:02 ET
Trinity Biotech Announces Entry into a Letter of Intent with Bayer for a Joint Partnership to Launch a CGM Biosensor Device in China and India
2024-01-31 12:00 ET
Trinity Biotech Announces Acquisition of the CGM Assets of Waveform Technologies, Inc.
2024-01-30 22:23 ET
Trinity Biotech plc to Host Investor Call
2023-12-27 13:57 ET
Trinity Biotech Announces It Has Begun Shipments of Its New HIV Screening Test, TrinScreen HIV to Kenya
2023-12-18 21:30 ET
Trinity Biotech Announces Management Changes
2023-11-28 21:05 ET
Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares
2023-10-10 12:15 ET
Trinity Biotech Welcomes The Decision Of The High Court Of Kenya To Strike Out The Applications To Prevent the Procurement of TrinScreen HIV By The Kenyan Ministry of Health
2023-10-03 13:15 ET
Trinity Biotech Announces Q2 2023 Financial Results
2023-09-27 16:50 ET
Trinity Biotech plc to Announce Second Quarter Fiscal Year 2023 Financial Results
2023-09-11 20:50 ET
Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Minimum Bid Price Requirement
2023-08-07 12:00 ET
Trinity Biotech Announces That It Has Received 510(k) Clearance From The U.S. Food and Drug Administration for the Premier Resolution System
2023-07-06 13:45 ET
Trinity Biotech Announces Q1 2023 Financial Results
2023-07-03 22:30 ET
Trinity Biotech plc to Announce First Quarter Fiscal Year 2023 Financial Results
2023-05-05 12:00 ET
Trinity Biotech Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
2023-04-27 18:50 ET
Trinity Biotech Announces the Successful Closing of the $30 Million Sale of its Life Sciences Supply Business to Biosynth
2023-04-24 21:50 ET
Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Minimum Bid Price Requirement
2023-04-20 12:30 ET
Trinity Biotech Announces the $30 Million Sale of its Life Sciences Supply Business to Biosynth
2023-03-23 12:50 ET
Trinity Biotech Announces Fourth Quarter and Fiscal Year 2022 Financial Results
2023-03-22 15:10 ET
Trinity Biotech Welcomes TrinScreen HIV’s Inclusion In The New Kenyan HIV Testing Algorithm
2023-03-16 19:30 ET
Trinity Biotech plc to Announce Fourth Quarter and Fiscal Year 2022 Financial Results
2023-02-22 13:30 ET
Trinity Biotech Announces Entry Into An Increased Loan Facility to Fund Potential Acquisitions
2023-01-09 13:00 ET
Trinity Biotech Announces Strategic Partnership with imaware™ to Deliver Integrated Diagnostic Testing Solutions to Digital Health Industry
2022-12-15 14:05 ET
Trinity Biotech Announces Q3 2022 Financial Results
2022-12-09 10:35 ET
Trinity Biotech plc to Announce Third Quarter Fiscal Year 2022 Financial Results
2022-11-30 10:50 ET
Trinity Biotech to participate in the Piper Sandler 34th Annual Healthcare Conference
2022-11-03 13:00 ET
Trinity Biotech Announces Quarter 2 2022 Financial Results And Preliminary Q3 2022 Revenue Guidance
2022-11-01 13:15 ET
Trinity Biotech plc to Announce Second Quarter Fiscal Year 2022 Financial Results
2022-10-26 12:30 ET
Trinity Biotech Announces the Appointment of Tom Lindsay to its Board of Directors
2022-10-03 12:50 ET
Trinity Biotech Announces The Appointment of Aris Kekedjian As Chairman and CEO
2022-09-30 13:00 ET
Trinity Biotech Announces Results of AGM
2022-06-30 13:07 ET
Trinity Biotech Announces Quarter 1 2022 Financial Results
2022-06-29 21:20 ET
Trinity Biotech plc to Announce First Quarter Fiscal Year 2022 Financial Results
2022-05-20 13:20 ET
Trinity Biotech Announces CE Mark of its 10-Minute Covid-19 Antigen Test
2022-05-03 22:50 ET
Trinity Biotech Announces the Successful Closing of its Strategic Investment and Partnership With The MiCo Group of South Korea
2022-04-11 13:00 ET
Trinity Biotech Announces Quarter 4 and Fiscal Year 2021 Financial Results
2022-04-11 12:15 ET
Trinity Biotech Announces A $45 Million Strategic Investment And Partnership With The MiCo Group of South Korea
2022-02-14 13:10 ET
Trinity Biotech Announces the World Health Organisation Approval Of TrinScreen™ HIV
2022-01-27 22:05 ET
Trinity Biotech Announces The Successful Closing of its Debt Refinancing
2022-01-25 13:15 ET
Trinity Biotech Announces That Its Shareholders Have Approved All of the Four Resolutions That Were the Subject of the EGM Held on January 25, 2022
2021-12-15 23:21 ET
Trinity Biotech Announces Q3 2021 Results, the Entry Into a $81,250,000 Loan Facility to Refinance the Company’s Exchangeable Senior Notes and Agreements To Repurchase Outstanding Exchangeable Senior Notes
2021-09-09 12:45 ET
Trinity Biotech Announces Results for Q2, 2021
2021-08-31 20:30 ET
Trinity Biotech plc to Announce Second Quarter Fiscal Year 2021 Financial Results
2021-07-16 12:00 ET
Trinity Biotech Provides A Business Development Update For Q2 2021
2021-05-25 12:48 ET
Trinity Biotech Announces Results for Q1, 2021
2021-05-19 16:43 ET
Trinity Biotech plc to Announce First Quarter Fiscal Year 2021 Financial Results
2021-03-30 13:00 ET
Trinity Biotech Announces the Submission of TrinScreen™ HIV to the World Health Organisation for Approval
2021-03-25 13:28 ET
Trinity Biotech Announces Quarter 4 and Fiscal Year 2020 Financial Results
2021-03-23 20:15 ET
Trinity Biotech plc to Announce Fourth Quarter and Fiscal Year 2020 Financial Results
2021-01-05 13:04 ET
Trinity Biotech Announces CE Mark of its Covid-19 IgG ELISA Antibody Test
2020-11-17 14:12 ET
Trinity Biotech Announces Results for Q3, 2020
2020-10-29 14:38 ET
Trinity Biotech plc to Announce Third Quarter 2020 Financial Results
2020-08-25 13:40 ET
Trinity Biotech Announces Results for Q2, 2020
2020-08-20 14:31 ET
Trinity Biotech announces EUA submission for Covid-19 ELISA Antibody test
2020-08-18 12:04 ET
Trinity Biotech plc to Announce Second Quarter 2020 Financial Results

SEC forms

Show financial reports only

SEC form 6
2024-02-16 18:02 ET
Trinity Biotech plc published news for 2023 q4
SEC form 6
2024-02-16 18:02 ET
Trinity Biotech plc published news for 2023 q4
SEC form 6
2024-02-16 18:00 ET
Trinity Biotech plc published news for 2023 q4
SEC form 6
2024-02-16 18:00 ET
Trinity Biotech plc published news for 2023 q4
SEC form 6
2024-02-01 11:37 ET
Trinity Biotech plc published news for 2023 q4
SEC form 6
2024-02-01 11:37 ET
Trinity Biotech plc published news for 2023 q4
SEC form 6
2024-02-01 11:33 ET
Trinity Biotech plc published news for 2023 q4
SEC form 6
2024-02-01 11:33 ET
Trinity Biotech plc published news for 2023 q4
SEC form 6
2024-02-01 11:33 ET
Trinity Biotech plc published news for 2023 q4
SEC form 6
2024-02-01 11:33 ET
Trinity Biotech plc published news for 2023 q4
SEC form 6
2024-02-01 11:33 ET
Trinity Biotech plc published news for 2023 q4
SEC form 6
2024-01-02 14:02 ET
Trinity Biotech plc published news for 2023 q4
SEC form 6
2024-01-02 14:02 ET
Trinity Biotech plc published news for 2023 q4
SEC form 6
2023-11-29 09:00 ET
Trinity Biotech plc published news for 2023 q3
SEC form 6
2023-11-29 09:00 ET
Trinity Biotech plc published news for 2023 q3
SEC form 6
2023-09-12 16:04 ET
Trinity Biotech plc published news for 2023 q2
SEC form 6
2023-09-06 16:04 ET
Trinity Biotech plc published news for 2023 q2
SEC form 6
2023-09-05 15:38 ET
Trinity Biotech plc published news for 2023 q2
SEC form 6
2023-07-10 06:02 ET
Trinity Biotech plc published news for 2023 q2
SEC form 6
2023-05-16 14:54 ET
Trinity Biotech plc published news for 2023 q1
SEC form 6
2023-05-08 09:04 ET
Trinity Biotech plc published news for 2023 q1
SEC form 6
2023-05-01 16:15 ET
Trinity Biotech plc published news for 2023 q1
SEC form 6
2023-05-01 13:43 ET
Trinity Biotech plc published news for 2023 q1
SEC form 6
2023-04-25 16:40 ET
Trinity Biotech plc published news for 2023 q1
SEC form 6
2023-04-24 07:26 ET
Trinity Biotech plc published news for 2023 q1
SEC form 6
2023-03-27 11:38 ET
Trinity Biotech plc published news for 2022 q4
SEC form 6
2023-03-27 06:01 ET
Trinity Biotech plc reported for 2022 q4
SEC form 6
2023-02-22 12:11 ET
Trinity Biotech plc published news for 2022 q4
SEC form 6
2023-01-10 16:05 ET
Trinity Biotech plc published news for 2022 q4
SEC form 6
2022-12-16 10:59 ET
Trinity Biotech plc reported for 2022 q3
SEC form 6
2022-12-09 10:52 ET
Trinity Biotech plc published news for 2022 q3
SEC form 6
2022-11-15 00:00 ET
Trinity Biotech plc published news for 2022 q3
SEC form 6
2022-11-04 11:08 ET
Trinity Biotech plc published news for 2022 q3
SEC form 6
2022-11-04 06:50 ET
Trinity Biotech plc published news for 2022 q3
SEC form 6
2022-11-02 12:56 ET
Trinity Biotech plc published news for 2022 q3
SEC form 6
2022-10-27 08:56 ET
Trinity Biotech plc published news for 2022 q3
SEC form 6
2022-10-04 06:12 ET
Trinity Biotech plc published news for 2022 q3
SEC form 6
2022-09-30 10:55 ET
Trinity Biotech plc published news for 2022 q2
SEC form 6
2022-09-16 11:25 ET
Trinity Biotech plc published news for 2022 q2
SEC form 6
2022-09-12 12:31 ET
Trinity Biotech plc published news for 2022 q2
SEC form 6
2022-09-12 12:22 ET
Trinity Biotech plc published news for 2022 q2
SEC form 6
2022-07-01 10:21 ET
Trinity Biotech plc published news for 2022 q2
SEC form 6
2022-05-25 15:24 ET
Trinity Biotech plc published news for 2022 q1
SEC form 6
2022-05-23 12:06 ET
Trinity Biotech plc published news for 2022 q1
SEC form 6
2022-05-09 09:12 ET
Trinity Biotech plc published news for 2022 q1
SEC form 6
2022-05-02 16:13 ET
Trinity Biotech plc published news for 2022 q1
SEC form 6
2022-04-11 12:22 ET
Trinity Biotech plc published news for 2022 q1
SEC form 6
2022-04-11 08:15 ET
Trinity Biotech plc published news for 2022 q1
SEC form 6
2022-02-11 06:18 ET
Trinity Biotech plc published news for 2021 q4
SEC form 6
2022-01-28 07:12 ET
Trinity Biotech plc published news for 2021 q4
SEC form 6
2022-01-25 12:12 ET
Trinity Biotech plc published news for 2021 q4
SEC form 6
2022-01-06 16:01 ET
Trinity Biotech plc published news for 2021 q4
SEC form 6
2021-12-23 17:00 ET
Trinity Biotech plc published news for 2021 q3
SEC form 6
2021-12-23 09:33 ET
Trinity Biotech plc published news for 2021 q3
SEC form 6
2021-12-16 07:25 ET
Trinity Biotech plc published news for 2021 q3
SEC form 6
2021-09-30 09:38 ET
Trinity Biotech plc published news for 2021 q2
SEC form 6
2021-09-17 16:36 ET
Trinity Biotech plc published news for 2021 q2
SEC form 6
2021-09-17 16:35 ET
Trinity Biotech plc published news for 2021 q2
SEC form 6
2021-09-17 16:33 ET
Trinity Biotech plc published news for 2021 q2
SEC form 6
2021-09-09 15:31 ET
Trinity Biotech plc published news for 2021 q2
SEC form 6
2021-07-19 16:23 ET
Trinity Biotech plc published news for 2021 q2
SEC form 6
2021-05-27 06:01 ET
Trinity Biotech plc published news for 2021 q1
SEC form 6
2021-04-30 16:10 ET
Trinity Biotech plc published news for 2021 q1
SEC form 6
2021-03-30 10:30 ET
Trinity Biotech plc published news for 2020 q4
SEC form 6
2021-03-26 12:30 ET
Trinity Biotech plc published news for 2020 q4
SEC form 6
2021-01-05 12:05 ET
Trinity Biotech plc published news for 2020 q4
SEC form 6
2020-12-08 09:50 ET
Trinity Biotech plc published news for 2020 q3
SEC form 6
2020-11-24 08:57 ET
Trinity Biotech plc published news for 2020 q3
SEC form 6
2020-11-17 12:19 ET
Trinity Biotech plc published news for 2020 q3
SEC form 6
2020-10-28 11:23 ET
Trinity Biotech plc published news for 2020 q3
SEC form 6
2020-10-28 11:21 ET
Trinity Biotech plc published news for 2020 q3